Baloxavir Marboxil
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB13997 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 12 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | acquired hemophagocytic lymphohistiocytosis associated with malignant disease | KG + DL |
| 2 | hemophagocytic syndrome associated with an infection | KG + DL |
| 3 | cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency | KG + DL |
| 4 | Singleton-Merten syndrome | KG + DL |
| 5 | hemophagocytic syndrome | KG + DL |
| 6 | chronic hepatitis C virus infection | KG + DL |
| 7 | hepatitis C virus infection | KG + DL |
| 8 | hepatitis E virus infection | KG + DL |
| 9 | hepatitis A virus infection | KG + DL |
| 10 | Omsk hemorrhagic fever | KG + DL |
| 11 | Kyasanur forest disease | KG + DL |
| 12 | hepatitis, viral, animal | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.